We are recruiting patients with triple negative breast cancer [Estrogen Receptor (ER) negative, Progesterone Receptor (PR) negative, and HER2 negative] which is an aggressive breast cancer type that has limited treatment options. Combination chemotherapy is usually given prior to surgery for this type of breast cancer in patients with stage II and III disease. Complete disappearance of all cancer in the breast and lymph nodes are observed in about 30 to 40% of treated patients. This has been shown to correlate with good prognosis. We just completed a small pilot study with combination chemotherapy in which 10 out of 10 (100%) of patients with triple negative breast cancer had complete disappearance of their disease. We are reopening the study for accrual of 15 more patients with stage II and III triple negative breast cancer who have not had definitive surgery (lumpectomy or mastectomy) to confirm our finding. The trial is open and will end with the recruitment of 15 patients.